3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Triple Negative Breast Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Lung Diseases
1
Liposarcoma
1
Endometrial Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma, Squamous Cell
1
Advanced Biliary Tract Cancer
1
Adenocarcinoma
1
Interventions
Cisplatin
101
Radiotherapy
53
Brachytherapy
41
Paclitaxel
37
Carboplatin
36
Surveys and Questionnaires
28
Blood Specimen Collection
20
pembrolizumab
19
Radiation
17
Magnetic Resonance Spectroscopy
17
Drug Therapy
17
Colposcopy
16
Methods
14
Bevacizumab
14
Early Intervention, Educational
12
toripalimab
11
Topotecan
11
Radiotherapy, Intensity-Modulated
11
Papanicolaou Test
11
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
11
Chemoradiotherapy
11
Biopsy
11
camrelizumab
10
Mass Screening
10
Gemcitabine
10
Patient Navigation
9
Papillomavirus Vaccines
9
Nivolumab
9
Fluorodeoxyglucose F18
9
Educational Status
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Uterine Cervical Neoplasms
×
sitravatinib
×
Clear all
NCT05614453
2023-06-29
ITTACC
Australia New Zealand Gynaecological Oncology Group
Phase 2
Withdrawn